TCO-PEG4-VC-PAB-MMAE (CAS: 2758671-45-1) is a cleavable linker-drug used in antibody-drug conjugate (ADC) development. It combines a trans-cyclooctene (TCO) group for bioorthogonal conjugation, a PEG4 spacer for flexibility, a Val-Cit (VC) dipeptide for enzyme-cleavable linkage, a PAB spacer for payload release, and MMAE, a potent cytotoxic agent targeting cancer cells.
Key Features:
- TCO Group: Enables rapid, bioorthogonal conjugation with tetrazine-containing antibodies.
- PEG4 Spacer: Enhances solubility and reduces steric hindrance.
- VC Linker: Cleaved by cathepsin B in tumor cells, ensuring targeted drug release.
- PAB Spacer: Ensures efficient payload release upon linker cleavage.
- MMAE: A powerful antimitotic agent that disrupts cell division.
Applications:
- Antibody-Drug Conjugates (ADCs): Enables precise, site-specific drug conjugation and controlled cytotoxic drug release.
- Targeted Cancer Therapy: Delivers MMAE directly to cancer cells, improving efficacy while reducing side effects.
This linker-drug system supports advanced ADC development, offering site-specific conjugation and selective drug release for cancer treatment.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
